Medicare Enrolled
Dr. Mary Milam, MD
Hematology & Oncology · Fort Worth, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Milam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Milam?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Milam
Dr. Mary Milam is a hematology & oncology specialist in Fort Worth, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Milam performed 11,461 Medicare services across 2,995 unique beneficiaries.
Between the years covered by Open Payments, Dr. Milam received a total of $21,550 from 93 pharmaceutical and/or device companies across 1254 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Milam is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 36% volume in TX
$21,550 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,461
Medicare services
Top 36% in TX for hematology & oncology
2,995
Unique beneficiaries
$21
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~573 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (ondansetron/Zofran) | 1,994 | $0 | $2 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,316 | $8 | $21 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,265 | $8 | $11 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,101 | $0 | $1 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
827 | $10 | $30 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
827 | $64 | $155 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
678 | $1 | $15 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
583 | $87 | $225 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
278 | $93 | $175 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
236 | $100 | $600 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
227 | $10 | $70 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
213 | $23 | $160 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
185 | $2 | $30 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
173 | $11 | $58 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
140 | $16 | $48 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
126 | $19 | $57 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
118 | $12 | $95 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
116 | $13 | $40 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
111 | $1 | $15 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
104 | $48 | $282 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
102 | $22 | $187 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
100 | $1 | $20 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
73 | $4 | $12 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
62 | $134 | $400 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
56 | $26 | $282 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
56 | $125 | $362 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $131 | $319 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
55 | $30 | $37 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
50 | $72 | $85 |
| Erythrocyte sedimentation rate (ESR) test A blood test that measures how quickly red blood cells settle in a test tube to detect inflammation in the body. This specific method is performed manually rather than using an automated machine. |
47 | $4 | $8 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
47 | $3 | $12 |
| PSA test (prostate cancer screening) | 42 | $18 | $70 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
33 | $16 | $55 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
18 | $28 | $111 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
16 | $39 | $100 |
| New patient office visit, complex (60-74 min) | 15 | $160 | $460 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
15 | $39 | $116 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.7% high complexity
32.0% medium
54.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$21,550
Total received (2018-2024)
Avg $3,079/year across 7 years
Top 19% in TX for hematology & oncology
93
Companies
1,254
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,133 (98.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$417 (1.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,726
2023
$3,898
2022
$3,278
2021
$2,942
2020
$2,031
2019
$3,092
2018
$2,583
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$2,171
Janssen Biotech, Inc.
$1,240
PFIZER INC.
$1,227
E.R. Squibb & Sons, L.L.C.
$1,078
Daiichi Sankyo Inc.
$991
Incyte Corporation
$922
Lilly USA, LLC
$896
Genentech USA, Inc.
$701
Rigel Pharmaceuticals, Inc.
$560
Merck Sharp & Dohme Corporation
$550
Celgene Corporation
$519
AstraZeneca Pharmaceuticals LP
$516
Seagen Inc.
$492
Exelixis Inc.
$449
Taiho Oncology, Inc.
$443
Eisai Inc.
$438
Gilead Sciences, Inc.
$429
Ipsen Biopharmaceuticals, Inc
$426
PharmaEssentia USA Corporation
$395
Kite Pharma, Inc.
$372
Merck Sharp & Dohme LLC
$334
Octapharma USA, Inc.
$329
Boehringer Ingelheim Pharmaceuticals, Inc.
$310
GENZYME CORPORATION
$292
Amgen Inc.
$271
Bayer HealthCare Pharmaceuticals Inc.
$256
GlaxoSmithKline, LLC.
$255
Lexicon Pharmaceuticals, Inc.
$235
Janssen Pharmaceuticals, Inc
$224
ABBVIE INC.
$207
Astellas Pharma US Inc
$201
PUMA BIOTECHNOLOGY, INC.
$192
ARRAY BIOPHARMA INC
$180
Karyopharm Therapeutics Inc.
$165
Bayer Healthcare Pharmaceuticals Inc.
$148
Acrotech Biopharma LLC
$145
Regeneron Healthcare Solutions, Inc.
$144
Seattle Genetics, Inc.
$131
SHIELD THERAPEUTICS INC
$130
Takeda Pharmaceuticals U.S.A., Inc.
$125
TAIHO ONCOLOGY, INC.
$112
Alexion Pharmaceuticals, Inc.
$105
Adaptive Biotechnologies Corporation
$98
EISAI INC.
$98
EMD Serono, Inc.
$97
Dendreon Pharmaceuticals LLC
$92
Pharmacyclics LLC, An AbbVie Company
$90
Mirati Therapeutics, Inc.
$89
Coherus Biosciences Inc.
$87
Dova Pharmaceuticals
$86
JAZZ PHARMACEUTICALS INC.
$82
AbbVie Inc.
$81
Epizyme, Inc.,
$80
Genmab U.S., Inc.
$64
Stemline Therapeutics Inc.
$64
Pharmacosmos Therapeutics Inc.
$63
AbbVie, Inc.
$61
SOBI, INC
$58
CTI BioPharma Corp.
$58
Fennec Pharmaceuticals, Inc.
$51
TESARO, Inc.
$47
Helsinn Therapeutics (U.S.), Inc.
$46
SERVIER PHARMACEUTICALS LLC
$43
Deciphera Pharmaceuticals Inc.
$40
TerSera Therapeutics LLC
$39
Accord Healthcare, Inc.
$38
EUSA Pharma (US) LLC
$36
Myovant Sciences Inc.
$35
Pharmacyclics LLC, an AbbVie Company
$32
Advanced Accelerator Applications
$31
MorphoSys, US Inc.
$30
Foundation Medicine, Inc.
$30
Nestle HealthCare Nutrition Inc.
$25
TG Therapeutics, Inc.
$24
Sun Pharmaceutical Industries Inc.
$23
MEDIVATION FIELD SOLUTIONS LLC
$22
INSYS Therapeutics Inc
$22
ADC Therapeutics America, Inc.
$21
Acrotech Biopharma Inc.
$21
IMMUNITYBIO, INC.
$20
Teva Pharmaceuticals USA, Inc.
$20
IBSA Pharma Inc.
$20
Jazz Pharmaceuticals Inc.
$19
Blueprint Medicines Corporation
$19
TG THERAPEUTICS, INC.
$19
BeiGene USA, Inc.
$19
Aveo Pharmaceuticals, Inc.
$19
Fresenius Kabi USA, LLC
$17
MENARINI SILICON BIOSYSTEMS, INC.
$15
Tempus AI, Inc
$15
Clovis Oncology, Inc.
$14
Azurity Pharmaceuticals, Inc.
$14
Aurobindo Pharma USA, Inc.
$11
Top 3 companies account for 21.5% of total payments
Associated products mentioned in payments ›
ACCRUFER · ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALPROLIX · ANKTIVA · AUGTYRO · AYVAKIT · Alecensa · Aliqopa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · CABOMETYX · CALQUENCE · CAMCEVI · CYRAMZA · Cabometyx · Cellsearch · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · Enhertu · Epkinly · Erivedge · Erleada · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Folotyn · GAZYVA · GILOTRIF · HEMADY · Herceptin · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · Inrebic · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kerendia · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lupron · Lutathera · MEKINIST · MONJUVI · Monoferric · NERLYNX · NINLARO · NUWIQ · Nexavar · Nplate · Nubeqa · OCTAGAM · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · Orserdu · PADCEV · PAXLOVID · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · Pedmark · Perjeta · Pomalyst · QINLOCK · REBLOZYL · RETEVMO · ROZLYTREK · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stimufend · Stivarga · Sylvant · TABRECTA · TAGRISSO · TALZENNA · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tibsovo · Tirosint · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VIVIMUSTA · VONJO · VOTRIENT · Venclexta · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYKADIA · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $188 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
47
Per 100K population
2.2
County median income
$81,905
Nearest hospital
JPS HEALTH NETWORK
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Milam is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 19% of TX peers, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Milam experienced with anti-nausea injection (ondansetron/zofran)?
Based on Medicare claims data, Dr. Milam performed 1,994 anti-nausea injection (ondansetron/zofran) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Milam receive payments from pharmaceutical companies?
Yes. Dr. Milam received a total of $21,550 from 93 companies across 1,254 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Milam's costs compare to other hematology & oncology specialists in Fort Worth?
Dr. Milam's average Medicare payment per service is $21. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Milam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fort Worth
Browse hematology & oncology specialists in Fort Worth ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology